The American Institute of Architects: Advocating for Public Relevance of Architecture While Driving Professionalism in the Design and Construction Industry

The American Institute of Architects is a Washington D.C-based professional body of architects and other associated partners that is redefining the design and construction industry. It was founded in 1857 by a group of 13 architects with the aim of supporting architects in their profession as well as to keep the profession relevant in the industry. The organization achieves its mission through public awareness, education, and advocacy.

Members Benefits

AIA has been very helpful to its members in several ways. It helps them maintain their licenses by sponsoring them to further their education. The upcoming architects benefit from the unlimited resources relevant to build their careers from the organization. AIA also ensures that the members are always abreast with the happenings in the construction and design industry particularly the economic status for their businesses. Through awards programs available at the organization, architects are compelled to give their best and maintain excellence in their works.

Leadership

AIA has reached greater heights with the help of experts such as Robert Ivy. He took up the leadership in 2011 and has since worked relentlessly to see the organization become influential and responsive in its activities. He has adopted modern technology in the firm to enhance smooth running of operations. He is also credited for aligning the administration that has enhanced decision -making processes. Ivy is a former student of The University of the South where he graduated in 1969 with a Bachelor of Arts degree in English. He then proceeded to Tulane University for his Master of Architecture graduating in 1976.

About Robert Ivy

Robert Ivy started his career in 1981 as a Principle for an architectural firm, Dean/Dale, Dean & Ivy. He left the company in 1996 to join Architectural Record as the Editor in Chief. He was very instrumental to the company in his 14 years tenure there, growing the architectural journal to an award-winning level. Among the honors that the journal received under his leadership include the American Society of Magazine Editors National Magazine Award for General Excellence and the premier magazine journalism award. The same duration, Robert worked for McGraw-Hill Construction as the Vice President and Editorial Director. In 1996, he joined the American Institute of Architects where he is currently working as the Executive Vice President and Chief Executive Officer.

Throughout his career, Robert has received several recognitions for his impressive work. The awards include the Crain Award by the American Business Media. He was also named the Master Architect by the National architecture fraternity, Alpha Rho Chi.

Amicus Therapeutics and the Treatment of Rare Diseases

Amicus Therapeutics is a biotechnology company that focuses on researching treatment for rare and orphan diseases. Although the company is based in Cranbury, New Jersey, they operate a second research site in San Diego, California. Amicus was founded in 2002 but didn’t go public until 2007. The company is fairly small, with around five hundred employees. Amicus is primarily research based and has to have other companies take care of manufacturing. Although the company offers no products as of 2017, a few potential products are in the final stages of being approved for commercial use.

https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo

Fabry Disease is one illness that Amicus Therapeutics is currently researching. The company has developed two potential products to help treat it: Galafold/Migalastat Monotherapy and novel ERTs (Enzyme Replacement Therapy). Galafold is an orally administered monotherapy that has full approval in Europe and is ready to be released to the public. Migalastat Monotherapy and Galafold are one in the same, with Galafold being the brand name. While the product is ready for use in Europe, it is still in the approval stages in the Americas and the rest of the world. Amicus’ ERTs for Fabry Disease are in preclinical stages of research.
In addition to Fabry Disease, Amicus Therapeutics studies two other illnesses specifically, Pompe Disease and Epidermolysis Bullosa. Their product for Pompe Disease, a novel ERT named ATB200 and AT2221 are in the middle of the final phase of testing. This treatment will require a chaperone as well. Amicus’ medication for Epidermolysis Bullosa is named SD-101. It is a topical medication. Currently, SD-101 is in the third and final phase of testing.
While Amicus Therapeutics focuses on a few diseases specifically, they also conduct research on other rare diseases and plan treatments for patients with these illnesses. Most of their medications for these various diseases are novel ERTs and most of them are in the primary research phase of development.
Dedicated to research and creating treatments for those with rare illnesses, Amicus Therapeutics is a company to keep an eye on. Several products are nearing their final stages and are one step closer to helping others survive.
More here: Crunchbase

Litigation Assistance With Karl Heideck

Litigation Assistance With Karl Heideck

Any time that you are looking to get everything you need in terms of your litigation, you’ll want to touch base with a company that can help you out with this. Karl Heideck is a great lawyer who can serve you with this. Before you reach out to Heideck for service, take the time to research litigation, the type of legal aid he provides and what you need to know about hiring the right lawyer who can assist you.

What is litigation and what do litigators do?

Litigation refers to the area of law in which cases are tried or settle for a number of matters. This applies both to civil litigation and criminal litigation. So whether you are filing a lawsuit for any reason or defending yourself from charges, it is incredibly important to reach out to a professional attorney that can serve you.

What are some areas of expertise that Karl Heideck practices?

Karl Heidecke specializes in a number of legal matters. First and foremost, he has expertise in litigation. He specializes in court cases involving people in the greater Philadelphia area and the surrounding area. In addition to litigation, Karl Heideck specializes to include compliance and risk management. Compliance revolves around making sure that another party is following a set of agreed-upon principles. This could refer to anything from entering a contract to negotiating and sticking to a collective bargaining agreement. Risk management allows a party to be sure that they are not falling prey to some legal liabilities which can be troublesome and expensive in the long run.

You will be in good hands by reaching out to Karl Heideck, because he has the experience and educational background to serve you. For example, he received his law degree with honors from Tempe University. In addition to litigation and compliance, Karl Heideck specializes in other areas, such as product liability and legal writing.

Take advantage of these tips so that you can make the most out of your legal needs.

For more, see https://members.nationalgeographic.com/804161697022/.